Doctors Question Evidence Behind Pentagon Plan for Testosterone Screening

The US military’s plan to screen active-duty and reserve service members for testosterone deficiency has sparked a heated debate among medical professionals, who warn that this policy may do more harm than good. The decision, spearheaded by Defense Secretary Pete Hegseth, aims to boost combat readiness by ensuring troops have optimal hormone levels.

However, experts argue that the scientific basis for this mandate is lacking. A broader trend of healthcare policy changes under the Trump administration has raised eyebrows among medical experts. For instance, Hegseth’s reversal of the military’s flu vaccine mandate was walked back after a flu outbreak highlighted its importance. Similarly, the Department of Health and Human Services’ removal of 17 members from its vaccine advisory panel and altered vaccine recommendations have sparked concerns about scientific integrity.

Studies on low testosterone replacement therapy primarily focus on older men, raising questions about its applicability to younger populations. Dr. Kevin McVary, a urologist and medical advisor for Rugiet, notes that treatment without symptoms can lead to overtreatment, which has adverse consequences.

The natural decline of testosterone levels with age is not an accurate benchmark for screening. According to Dr. Haleem Mohammed, chief medical officer at Gameday Health, “There is a population-level decline of 1% per year after ages 30-40 that accelerates as you get older.” However, individual patterns vary greatly, and relying on age alone may not accurately identify those who require treatment.

The FDA’s recent revision of testosterone labels to remove warnings about increased risks of heart attack or stroke highlights the complexities involved. A study led by Dr. Steven Nissen at the Cleveland Clinic found that while participants showed higher rates of atrial arrhythmia and bone fractures, these findings may have implications for military personnel. Other experts warn about the severe impact of testosterone therapy on male fertility, which could be particularly devastating for young service members who are not yet done having families.

Hegseth’s justification for testing – to address operator syndrome in special forces warriors – raises further concerns. Special forces operators are not representative of all active-duty and reserve members, notes Dr. B Christopher Frueh of the University of Hawaii, whose team first described the syndrome in 2020. These operators have unique exposures that may not be applicable to other soldiers.

While medical professionals emphasize potential benefits from appropriate testosterone testing, they caution against over-screening and overtreatment. Gameday Health’s Mohammed highlights the importance of identifying reversible causes of low testosterone, such as weight gain, which can be addressed through lifestyle changes rather than replacement therapy.

The Pentagon’s testosterone screening policy is a prime example of how well-intentioned but misguided healthcare initiatives can have far-reaching consequences. As medical professionals warn against the potential risks, it remains to be seen whether this policy will lead to improved combat readiness or merely create a new set of problems for service members and their families.